In experimental models of NO-dependent hypertension, naringenin treatment reduced the expression of Ang II converting enzyme type 1 (ACE1), Ang II synthesis, oxidative stress, kidney damage, and cardiac hypertrophy. This evidence concerns the gene AGT and hypertensive disorder.